Clearmind Medicine Inc. Common Shares (CMND) - Total Liabilities
Based on the latest financial reports, Clearmind Medicine Inc. Common Shares (CMND) has total liabilities worth $2.90 Million USD as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Clearmind Medicine Inc. Common Shares operating cash flow efficiency to assess how effectively this company generates cash.
Clearmind Medicine Inc. Common Shares - Total Liabilities Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Clearmind Medicine Inc. Common Shares to evaluate the company's liquid asset resilience ratio.
Clearmind Medicine Inc. Common Shares Competitors by Total Liabilities
The table below lists competitors of Clearmind Medicine Inc. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eezy PLC
HE:EEZY
|
Finland | €82.42 Million |
|
Alpha Compute Corp
NASDAQ:ALP
|
USA | $21.70 Million |
|
Eminence Minerals Limited
AU:EMA
|
Australia | AU$486.44K |
|
Boqii Holding Limited
NYSE:BQ
|
USA | $122.33 Million |
|
Gencell Ltd
TA:GNCL
|
Israel | ILA2.90 Million |
|
UNIDOC HEALTH CORP.
F:L7T
|
Germany | €2.33 Million |
|
N1 Holdings Ltd
AU:N1H
|
Australia | AU$166.62 Million |
|
Thunderstruck Resources Ltd
V:AWE
|
Canada | CA$747.18K |
Liability Composition Analysis (2014–2025)
This chart breaks down Clearmind Medicine Inc. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Clearmind Medicine Inc. Common Shares market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clearmind Medicine Inc. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clearmind Medicine Inc. Common Shares (2014–2025)
The table below shows the annual total liabilities of Clearmind Medicine Inc. Common Shares from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $4.89 Million | -15.31% |
| 2024-10-31 | $5.77 Million | +16.18% |
| 2023-10-31 | $4.97 Million | +89.48% |
| 2022-10-31 | $2.62 Million | +810.11% |
| 2021-10-31 | $288.19K | +2773.31% |
| 2020-10-31 | $10.03K | -70.37% |
| 2019-10-31 | $33.85K | +481.06% |
| 2018-10-31 | $5.83K | -88.64% |
| 2017-10-31 | $51.28K | +2.55% |
| 2016-10-31 | $50.01K | +129.78% |
| 2015-10-31 | $21.76K | -30.75% |
| 2014-10-31 | $31.43K | -- |
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more